| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7638140 | SOMERSET | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
May, 2018
(5 years ago) | |
| US7070808 | SOMERSET | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
May, 2018
(5 years ago) | |
| US7150881 | SOMERSET | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
Jun, 2018
(5 years ago) | |
Emsam is owned by Somerset.
Emsam contains Selegiline.
Emsam has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Emsam are:
- US7638140
- US7070808
- US7150881
Emsam was authorised for market use on 27 February, 2006.
Emsam is available in film, extended release;transdermal dosage forms.
The generics of Emsam are possible to be released after 12 June, 2018.
Drugs and Companies using SELEGILINE ingredient
Market Authorisation Date: 27 February, 2006
Treatment: NA
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
More Information on Dosage
EMSAM family patents
